Regeneron Pharmaceuticals Inc (BSP:REGN34)
R$ 89.25 1.25 (1.42%) Market Cap: 590.31 Bil Enterprise Value: 549.72 Bil PE Ratio: 24.59 PB Ratio: 3.63 GF Score: 86/100

Regeneron Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 08, 2021 / 02:30PM GMT
Release Date Price: R$42.5 (-2.41%)
Terence C. Flynn
Goldman Sachs Group, Inc., Research Division - MD

Good morning, everybody. Thanks for joining us. I'm Terence Flynn, the U.S. biopharma analyst at Goldman Sachs. We're very pleased to have Regeneron this morning. From the company, we have Israel Lowy, who is Senior Vice President, Translational and Clinical Sciences, Oncology; and Andres Sirulnik, who is Senior Vice President, Translational and Clinical Sciences, Hematology.

Before we get started, I'm going to turn it over to Justin Holko from the IR team, and then we'll dive into Q&A.

Justin Holko
Regeneron Pharmaceuticals, Inc. - VP of IR

Thank you, Terence. Before we begin, I'd like to remind you that remarks made on today's event will include forward-looking statements about Regeneron. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in the statement. A more complete description of these and other material risks can be found in Regeneron's SEC filings. We do not undertake

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot